Extended Data Table 7 Shift change in body mass index from baseline to week 96

From: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

  1. * Tables show the number of participants by BMI category at week 96, by treatment group and by sex; and the proportion of total participants within that treatment group and sex. The assessable population excludes 7 female participants (2 in
  2. long-acting therapy, 5 in oral therapy arm) who were pregnant at any time during the 180 days prior to the week 96 visit; and
  3. 9 participants (4 long-acting therapy group, 5 oral therapy group) who withdrew from the trial or died before week 96. Cells highlighted in yellow indicate shift to higher BMI category; cells highlighted in blue indicate shift to lower BMI category.
Back to article page